Q-omics provides the consensus-scored TMOD4 profile across patient tissues and cancer cell-line models. TMOD4 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMOD4 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, TMOD4 RNA expression shows 12,548 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, and HNSC as cancer lineages where TMOD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMOD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMOD4 survival associations across molecular data types. TMOD4 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMOD4 RNA expression–survival associations across cancer types. High TMOD4 expression shows unfavorable associations in MESO, BLCA, CHOL, PAAD, UCS and GBM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TMOD4 RNA expression.
This table summarizes TMOD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TMOD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMOD4 shows lower tumor expression in HNSC. The HNSC box plot shows higher TMOD4 RNA expression in normal versus tumor tissue (log2 FC = −0.020, t-test p = .003).
This table shows molecular features associated with TMOD4 in patient tissues and cancer cell lines. In patient samples, TMOD4 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMOD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and URINARY_TRACT.
